Back to Search Start Over

Real-Life Data on Hydroxychloroquine or Chloroquine with or Without Azithromycin in COVID-19 Patients: A Retrospective Analysis in Brazil.

Authors :
Souza-Silva MVR
Pereira DN
Pires MC
Vasconcelos IM
Schwarzbold AV
Vasconcelos DH
Pereira EC
Manenti ERF
Costa FR
Aguiar FC
Anschau F
Bartolazzi F
Nascimento GF
Vianna HR
Batista JDL
Machado-Rugolo J
Ruschel KB
Ferreira MAP
Oliveira LS
Menezes LSM
Ziegelmann PK
Tofani MGT
Bicalho MAC
Nogueira MCA
Guimarães-Júnior MH
Aguiar RLO
Rios DRA
Polanczyk CA
Marcolino MS
Source :
Arquivos brasileiros de cardiologia [Arq Bras Cardiol] 2023 Sep; Vol. 120 (9), pp. e20220935.
Publication Year :
2023

Abstract

Background: Despite no evidence showing benefits of hydroxychloroquine and chloroquine with or without azithromycin for COVID-19 treatment, these medications have been largely prescribed in Brazil.<br />Objectives: To assess outcomes, including in-hospital mortality, electrocardiographic abnormalities, hospital length-of-stay, admission to the intensive care unit, and need for dialysis and mechanical ventilation, in hospitalized COVID-19 patients who received chloroquine or hydroxychloroquine, and to compare outcomes between those patients and their matched controls.<br />Methods: A retrospective multicenter cohort study that included consecutive laboratory-confirmed COVID-19 patients from 37 Brazilian hospitals from March to September 2020. Propensity score was used to select matching controls by age, sex, cardiovascular comorbidities, and in-hospital use of corticosteroid. A p-value <0.05 was considered statistically significant.<br />Results: From 7,850 COVID-19 patients, 673 (8.6%) received hydroxychloroquine and 67 (0.9%) chloroquine. The median age in the study group was 60 years (46 - 71) and 59.1% were women. During hospitalization, 3.2% of patients presented side effects and 2.2% required therapy discontinuation. Electrocardiographic abnormalities were more prevalent in the chloroquine/hydroxychloroquine group (13.2% vs. 8.2%, p=0.01), and the long corrected QT interval was the main difference (3.6% vs. 0.4%, p<0.001). The median hospital length of stay was longer in the HCQ/CQ + AZT group than in controls (9.0 [5.0, 18.0] vs. 8.0 [4.0, 14.0] days). There was no statistical differences between groups in intensive care unit admission (35.1% vs. 32.0%; p=0.282), invasive mechanical ventilation support (27.0% vs. 22.3%; p=0.074) or mortality (18.9% vs. 18.0%; p=0.682).<br />Conclusion: COVID-19 patients treated with chloroquine or hydroxychloroquine had a longer hospital length of stay, when compared to matched controls. Intensive care unit admission, invasive mechanical ventilation, dialysis and in-hospital mortality were similar.

Details

Language :
English; Portuguese
ISSN :
1678-4170
Volume :
120
Issue :
9
Database :
MEDLINE
Journal :
Arquivos brasileiros de cardiologia
Publication Type :
Academic Journal
Accession number :
37878893
Full Text :
https://doi.org/10.36660/abc.20220935